SCHEDULE 13G/A: AIGH Capital Management and Orin Hirschman Disclose 9.9% Passive Stake in Grace Therapeutics

AIGH Capital Management, LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. as of March 31, 2025.

Summary

• AIGH Capital Management, LLC, AIGH Investment Partners, L.L.C., and Orin Hirschman (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13G.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 1,322,379 shares of Grace Therapeutics, Inc. Common Stock.
• This ownership represents 9.9% of the outstanding class of securities.
• The filing indicates that 824,742 common shares issuable upon the exercise of warrants are excluded from the reported beneficial ownership amount, as they are not currently exercisable due to beneficial ownership limitations.
• Orin Hirschman, as the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, holds sole voting and dispositive power over the reported shares.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Grace Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a 13G is a routine disclosure, the presence of a significant institutional investor holding a stake can be seen as a positive signal of confidence in the company, even if passive.

Positives

• The disclosure of a significant passive stake by institutional investors like AIGH Capital Management can signal confidence in the company's long-term prospects.
• The continued holding of a substantial stake by the Reporting Persons suggests ongoing belief in the value of Grace Therapeutics, Inc.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

This filing indicates continued investor interest in Grace Therapeutics, Inc., a company operating in the biotechnology or pharmaceutical sector, given its name. The passive nature of the investment suggests a belief in the company's existing strategy rather than an intent to drive change.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes, which can influence investor perception and potentially liquidity.

Key Dates

Keywords

Grace Therapeutics, AIGH Capital Management, Orin Hirschman, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing